Jonathan Chang
Stock Analyst at Leerink Partners
(0.59)
# 4,088
Out of 5,182 analysts
76
Total ratings
28.57%
Success rate
-21.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $8.41 | +54.58% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $20.41 | +267.47% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $27.50 | -1.82% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $30.83 | +140.03% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $31.04 | -64.56% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $10.55 | +383.41% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $5.89 | +1,173.34% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $5.05 | +890.10% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $99.12 | -69.73% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $3.07 | +290.88% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $10.35 | +151.21% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $8.61 | +225.20% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $12.81 | +313.74% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $8.41
Upside: +54.58%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $20.41
Upside: +267.47%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $27.50
Upside: -1.82%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $30.83
Upside: +140.03%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $31.04
Upside: -64.56%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $10.55
Upside: +383.41%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $5.89
Upside: +1,173.34%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $5.05
Upside: +890.10%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $99.12
Upside: -69.73%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $3.07
Upside: +290.88%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $10.35
Upside: +151.21%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $8.61
Upside: +225.20%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $12.81
Upside: +313.74%